U.S Secondary Hyperparathyroidism Treatment Market: 2020 Worldwide Opportunities, Market Share, Key Players

The increasing launch of effective drugs is a key factor driving the U.S. secondary hyperparathyroidism treatment market, says Fortune Business Insights in a report, titled "Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026." The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%.

Highlights of the Report:

o In-depth analysis of various insights, namely, U.S Secondary Hyperparathyroidism Treatment Market trends, growth drivers, opportunities, and other related challenges.
o Comprehensive details of key market players, their core competencies, and U.S Secondary Hyperparathyroidism Treatment Market share.
o The potency of suppliers and buyers to make better business decisions.
o Lists out the market size in terms of volume.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Key Players Operating in The U.S Secondary Hyperparathyroidism Treatment Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

o Amgen Inc.
o Teva Pharmaceutical Industries Ltd.
o Genzyme Corporation (Sanofi)
o AbbVie Inc.
o Cipla Inc.
o Dr. Reddy's Laboratories Ltd.
o OPKO Health, Inc.
o Other Prominent Players

Emerging Guidelines By Government Authorities Will Boost Growth
The increasing government initiatives for improvising secondary hyperparathyroidism management will create growth opportunities for the secondary hyperparathyroidism treatment market. The aim of SHPT treatment is to manage the biochemical markers of bone and mineral metabolism, which are directly linked to cardiovascular events and bone fractures by extensive epidemiologic evidence. International & national organizations in the U.S. and working groups such as the National Kidney Foundation have published various clinical guidance documents to encourage best practices in managing SHPT. Furthermore, increasing awareness about SHPT in physicians, as well as clinical specialists, have improved the treatment regimen for its management. The improvement in earlier identification and assessment of SHPT for mineral metabolism in CKD & ESRD will have a positive impact on secondary hyperparathyroidism treatment market growth. The reduction in associated complications for the management of SHPT is expected to accelerate growth of the market during the forecast period.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth
The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market. The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Secondary Hyperparathyroidism, 2018
4.2 Distribution of Secondary Hyperparathyroidism Patients by Treatment Type - Surgery, Drugs and Others, 2018
4.3 Key Industry Developments - Mergers, Acquisitions and Partnerships
4.4 Pipeline Analysis
4.5 Reimbursement Scenario
4.6 Cost Burden of Secondary Hyperparathyroidism
5. U.S. Secondary Hyperparathyroidism Treatment Market Analysis, Insights, and Forecast, 2015-2026
5.1. Market Analysis, Insights, and Forecast - By Drug Class
5.1.1 Calcimimetics
5.1.2 Vitamin D Analogues
5.1.3 Phosphate Binders
5.2. Market Analysis, Insights, and Forecast - By Distribution Channel
5.2.1 Hospital & Retail Pharmacies
5.2.2 Online Pharmacies
5.2.3 Others
5.3. Market Analysis, Insights, and Forecast - By Region
5.3.1 West
5.3.2 Midwest
5.3.3 South
5.3.4 Northeast
6. Competitive Analysis
6.1. Key Industry Developments
6.2. U.S. Market Share Analysis (2018)
6.3. Competition Dashboard
6.4. Comparative Analysis - Major Players
6.5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
6.5.1 Teva Pharmaceutical Industries Ltd.
6.5.2 Genzyme Corporation (Sanofi)
6.5.3 AbbVie Inc.
6.5.4 Cipla Inc.
6.5.5 Dr. Reddy's Laboratories Ltd.
6.5.6 Amgen Inc.
6.5.7 OPKO Health, Inc.
7. Strategic Recommendations
Continued...

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.